Danish DES registry
This article was originally published in The Gray Sheet
Johnson & Johnson/Cordis' Cypher sirolimus-eluting coronary stent has a lower nine-month target lesion revascularization rate than Boston Scientific's paclitaxel-eluting Taxus stent in the 4,432-patient Western Denmark Heart Registry, according to data published June 1 in Heart. In small vessels (less than 2.8 mm in diameter) the revascularization rates were 2.9% and 4.8% for Cypher and Taxus, respectively, a 40% difference in relative risk. In larger vessels, patients treated with Cypher had a 2.4% TLR rate versus 3% for Taxus, a statistically insignificant difference...
You may also be interested in...
Unilever North America agrees SmartyPant, founded in 2011 to create a comprehensive supplement made from premium ingredients to support the wellbeing needs of children and adults. Kind, fully owned by Mars, has an agreement to acquire family-owned Nature's Bakery which offers snacks including fig bars and other soft-baked foods.
Arcadia prohibited from arguing against Advantice’s appeal of National Advertising Division decision that Kerasal Fungal Nail Renewal ad claims weren’t supported. Arcadia violated confidentiality rule by publicizing NAD decision before the review was officially closed.
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.